^
    almost2years
    Pleomorphic xanthoastrocytoma. BRAF mutation and homozygous CDKN2A and/or B deletion. (@GustavoGaravag4)
    BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    BRAF mutation • CDKN2A deletion • CDKN2A mutation
    almost2years
    Sharing research ⁦@BrownUCancer⁩ ⁦with ⁦@BrownMedicine⁩ med student Taylor Arnoff MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics & immunotherapy https://t.co/1NBaURjiyo (@weldeiry)
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MDM2 (E3 ubiquitin protein ligase) • MDM4 (The mouse double minute 4)
    |
    CDKN2A deletion • MDM4 amplification
    almost2years
    Happy to share our latest research: MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy https://t.co/l0Q2QWiO6Z #eldeirylab @BrownUCancer @BrownMedicine @BrownUniversity (@weldeiry)
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MDM2 (E3 ubiquitin protein ligase) • MDM4 (The mouse double minute 4)
    |
    CDKN2A deletion • MDM4 amplification
    2years
    IDH mutant astrocytoma . need to do NGS and DNA methylation profile to look for CDKN2A homozygos deletion or other specific alterations. (@RawiaMo57385655)
    Next-generation sequencing • Epigenetic controller
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion
    almost3years
    I’m a colon cancer patient with a CDKN2A deep deletion. I’m not sure what deep deletion means. This isn’t a germline mutation, but from the tumor. An Ibrance trial came up on the paper with the results. Have you heard of colon cancer patients with peri mets using ibrance? (@SSpitalny)
    Clinical
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion
    |
    Ibrance (palbociclib)
    over3years
    What Is the Role of CDKN2A/B Homozygous Deletion in IDH–Mutant Astrocytoma? Dr. Sani H. Kizilbash answers in-depth for #ASCODailyNews https://t.co/9d4MtW0szA #BTSM (@ASCO)
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion